eligibility_summary
Adults (>18) with relapsed multiple myeloma after allogeneic transplant, measurable disease, ≥2 prior lines, off immunosuppression ≥1 month, no active GVHD, ECOG 0–1, life expectancy >3 months, consented. Exclude: active immunosuppression, prior anti-BCMA CAR-T, ALC <0.2x10^9/L, recent malignancy, active infection (HIV/HBV/HCV), uncontrolled illness, major organ dysfunction, AL amyloidosis/POEMS, pregnancy/lactation, inadequate contraception, lymphodepletion contraindication, hypersensitivity.
trial_source
clinical_trials.gov from Dec 2, 2025
annotation_status
ai
ai_summary
Intervention: CARTemis-1, an anti-BCMA CAR-T cell therapy (genetically engineered T-lymphocyte, cellular immunotherapy) given IV with 3+3 dose escalation (up to 6×10^6 CAR-T/kg). Mechanism of action: Patient T cells are modified to express a chimeric antigen receptor targeting B-cell maturation antigen (BCMA), CAR engagement activates T-cell cytotoxicity (degranulation, cytokine release, proliferation) to eliminate BCMA+ myeloma cells. Control mechanism: The construct includes EGFR expression as a built-in safety/control feature to manage treatment-related complications. Targets: BCMA-expressing malignant plasma cells in multiple myeloma, pathways include CAR-driven T-cell activation (CD3ζ/co-stimulation), immune synapse formation, and apoptosis of tumor cells, indirectly modulates the tumor immune microenvironment post–allo-transplant.